drugset
drugset / Trial / NCT05158439

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Tourette Syndrome

NCT05158439 ↗

Phase 1 Withdrawn The Foundation for Orthopaedics and Regenerative Medicine
NaSingle-groupOpen-labelTreatment

Summary

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Tourette Syndrome

Timeline

Start
2022-01
Primary completion
2026-01
Completion
2026-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AlloRx Cell therapy 1e+08 cells Intravenous

Indications

Tourette syndrome